Share

An update on SPECTA

The next generation sequencing service provider for SPECTA, 14M Genomics, has decided to close down operations due to withdrawal of funding from Syncona LLP, the sole investor of 14M Genomics. At this time, more than 850 patients have been included in SPECTAcolor and more than 120 patients have been included in SPECTAlung. More than 500 tumor samples have been tested by next generation sequencing and result reports are available.

EORTC is in the process of identifying a new service provider for next generation sequencing services. In addition, we have started talking to providers of different technologies, realizing that next generation sequencing is a powerful tool but often cannot be used in isolation for patient selection for clinical trials. Depending on the scientific and financing requirements of EORTC groups for the SPECTA platforms, different technologies can be used routinely or selectively for various patient cohorts. The EORTC board remains committed to the SPECTA philosophy and platforms and, together with the EORTC HQ and the SPECTA steering committees, are working hard to identify an adequate quality provider for molecular testing. The collection of biological material and clinical data continues in the same manner, as well as testing within specific clinical projects. More information will follow as soon as it becomes available.

Back to news list

Related News

  • Dr Denis Lacombe, EORTC CEO, appointed stakeholder co-chair of ACT EU advisory group

  • Clinical Trials Day 2024: a Q&A on pragmatic clinical trials

  • EORTC/EMA workshop suggests an international way forward for treatment optimisation studies

  • EORTC’s Participation at the ESTRO Congress 2024

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023